XNAS:ALOG Analogic Corp Quarterly Report 10-Q Filing - 1/31/2012

Effective Date 1/31/2012

XNAS:ALOG (Analogic Corp): Fair Value Estimate
Premium
XNAS:ALOG (Analogic Corp): Consider Buying
Premium
XNAS:ALOG (Analogic Corp): Consider Selling
Premium
XNAS:ALOG (Analogic Corp): Fair Value Uncertainty
Premium
XNAS:ALOG (Analogic Corp): Economic Moat
Premium
XNAS:ALOG (Analogic Corp): Stewardship
Premium
 
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2012

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to                 

Commission File Number 0-6715

 

 

ANALOGIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Massachusetts   04-2454372

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

8 Centennial Drive, Peabody, Massachusetts   01960
(Address of principal executive offices)   (Zip Code)

(978) 326-4000

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report.)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  ¨       Accelerated filer  x
Non-accelerated filer  ¨  (Do not check if a smaller reporting company)    Smaller reporting company  ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes  ¨    No  x

The number of shares of common stock outstanding at February 29, 2012 was 12,258,580.

 

 

 


Table of Contents

ANALOGIC CORPORATION

TABLE OF CONTENTS

 

           Page No.  
Part I. Financial Information   

Item 1.

  

Financial Statements

  
  

Unaudited Consolidated Balance Sheets as of January 31, 2012 and July 31, 2011

     3   
  

Unaudited Consolidated Statements of Operations for the Three and Six Months Ended
January 31, 2012 and 2011

     4   
  

Unaudited Consolidated Statements of Cash Flows for the Six Months Ended
January 31, 2012 and 2011

     5   
  

Notes to Unaudited Consolidated Financial Statements

     6   

Item 2.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     23   

Item 3.

  

Quantitative and Qualitative Disclosures About Market Risk

     32   

Item 4.

  

Controls and Procedures

     33   
Part II. Other Information   

Item 1A.

  

Risk Factors

     33   

Item 2.

  

Unregistered Sales of Equity Securities and Use of Proceeds

     33   

Item 4.

  

Mine Safety Disclosures

     34   
Item 6.    Exhibits      35   
Signatures      36   
Exhibit Index      37   

 

2


Table of Contents

Part I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

ANALOGIC CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except per share data)

 

     January 31,
2012
          July 31,
2011
 
Assets         

Current assets:

        

Cash and cash equivalents

   $ 174,306          $ 169,656   

Accounts receivable, net of allowance for doubtful accounts of $722 and $599 as of January 31, 2012 and July 31, 2011, respectively

     77,964            88,558   

Inventories

     103,768            105,483   

Refundable and deferred income taxes

     6,565            9,677   

Other current assets

     7,550              9,839   

Total current assets

     370,153            383,213   

Property, plant, and equipment, net

     92,854            83,157   

Goodwill and intangible assets, net

     37,720            39,252   

Other assets

     6,944            7,711   

Deferred income tax assets

     8,877              8,219   

Total Assets

   $ 516,548            $ 521,552   
Liabilities and Stockholders’ Equity         

Current liabilities:

        

Accounts payable

   $ 33,149          $ 37,478   

Accrued liabilities

     32,437            41,438   

Advance payments and deferred revenue

     10,384            9,249   

Accrued income taxes

     763              661   

Total current liabilities

     76,733            88,826   

Long-term liabilities:

        

Accrued income taxes

     5,270            5,322   

Other long-term liabilities

     2,987              3,932   

Total long-term liabilities

     8,257            9,254   

Commitments and guarantees (Note 15)

        

Stockholders’ equity:

        

Common stock, $0.05 par value

     613            627   

Capital in excess of par value

     91,286            85,407   

Retained earnings

     333,229            325,941   

Accumulated other comprehensive income

     6,430              11,497   

Total stockholders’ equity

     431,558              423,472   

Total Liabilities and Stockholders’ Equity

   $ 516,548            $ 521,552   

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

3


Table of Contents

ANALOGIC CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

 

     Three Months Ended
January 31,
         Six Months Ended
January 31,
 
     2012          2011          2012          2011  

Net revenue:

                 

Product

   $ 122,189         $ 111,315         $ 236,196         $ 208,004   

Engineering

     4,244             5,938             8,094             13,071   

Total net revenue

     126,433             117,253             244,290             221,075   

Cost of sales:

                 

Product

     75,705           70,596           146,936           129,652   

Engineering

     3,883             5,848             7,483             11,595   

Total cost of sales

     79,588             76,444             154,419             141,247   

Gross profit

     46,845             40,809             89,871             79,828   

Operating expenses:

                 

Research and product development

     13,940           14,769           29,207           28,673   

Selling and marketing

     10,605           10,716           21,070           20,324   

General and administrative

     14,509           9,320           26,219           19,067   

Restructuring

     -             (134          -             3,428   

Total operating expenses

     39,054             34,671             76,496             71,492   

Income from operations

     7,791             6,138             13,375             8,336   

Other income (expense):

                 

Interest income, net

     133           188           269           406   

Gain on sale of other investments

     2,500           -           2,500           -   

Other, net

     322             (100          497             (376

Total other income, net

     2,955             88             3,266             30   

Income from continuing operations before income taxes

     10,746           6,226           16,641           8,366   

Provision for (benefit from) income taxes

     (8,869          930             (7,000          1,689   

Income from continuing operations

     19,615           5,296           23,641           6,677   

Income from discontinued operations (net of income tax provision of $168)

     -           -           -           289   

Gain on disposal of discontinued operations (net of income tax provision of $505)

     -             -             -             924   

Net income

   $ 19,615           $ 5,296           $ 23,641           $ 7,890   

Basic net income per share:

                                               

Income from continuing operations

   $ 1.61         $ 0.42         $ 1.90         $ 0.53   

Income from discontinued operations, net of tax

     -           -           -           0.02   

Gain on disposal of discontinued operations, net of tax

     -             -             -             0.08   

Basic net income per share

   $ 1.61           $ 0.42           $ 1.90           $ 0.63   

Diluted net income per share:

                                               

Income from continuing operations

   $ 1.59         $ 0.42         $ 1.88         $ 0.53   

Income from discontinued operations, net of tax

     -           -           -           0.02   

Gain on disposal of discontinued operations, net of tax

     -             -             -             0.07   

Diluted net income per share

   $ 1.59           $ 0.42           $ 1.88           $ 0.62   

Weighted average shares outstanding:

                 

Basic

     12,188           12,574           12,464           12,599   

Diluted

     12,333           12,655           12,595           12,672   

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 

4


Table of Contents

ANALOGIC CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

     Six Months Ended
January 31,
 
     2012          2011  

OPERATING ACTIVITIES:

       

Net income

   $ 23,641         $ 7,890   

Less:

       

Income from discontinued operations

     -           289   

Gain on disposal of discontinued operations

     -             924   

Income from continuing operations

     23,641             6,677   

Adjustments to reconcile income from continuing operations to net cash provided by operating activities:

       

Provision for (benefit from) deferred income taxes

     2,213           (2,194

Depreciation and amortization

     9,205           8,756   

Allowance for doubtful accounts

     237           (9

Gain on sale of other investments

     (2,500        -   

Net (gain) loss on sale of property, plant, and equipment

     (20        2   

Bargain purchase gain

     -           (1,042

Share-based compensation expense

     5,401           4,552   

Fair value adjustment of contingent consideration

     43           -   

Excess tax provision for share-based compensation

     (21        96   

Net changes in operating assets and liabilities, net of acquired business (Note 12)

     624             (9,290

NET CASH PROVIDED BY CONTINUING OPERATIONS FOR OPERATING ACTIVITIES

     38,823           7,548   

NET CASH USED FOR DISCONTINUED OPERATIONS FOR OPERATING ACTIVITIES

     -             (335

NET CASH PROVIDED BY OPERATING ACTIVITIES

     38,823             7,213   

INVESTING ACTIVITIES:

       

Proceeds from sale of discontinued operations, net

     -           10,467   

Acquisition of business

     -           (346

Additions to property, plant, and equipment

     (17,278        (12,048

Proceeds from the sale of other investments

     2,500           -   

Proceeds from the sale of property, plant, and equipment

     28             123   

NET CASH USED FOR INVESTING ACTIVITIES

     (14,750          (1,804

FINANCING ACTIVITIES:

       

Issuance of stock pursuant to exercise of stock options, employee stock purchase plan, restricted stock plans, and non-employee director stock plan

     446           273   

Excess tax provision for share-based compensation

     21           (96

Purchase of common stock

     (15,612        (11,149

Dividends paid to shareholders

     (2,609          (2,605

NET CASH USED FOR FINANCING ACTIVITIES

     (17,754          (13,577

EFFECT OF EXCHANGE RATE CHANGES ON CASH

     (1,669          1,509   

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

     4,650             (6,659

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

     169,656             169,254   

CASH AND CASH EQUIVALENTS, END OF PERIOD

   $ 174,306           $ 162,595   

Supplemental disclosures of cash flow information:

       

Refunds received (cash paid) for income taxes, net

   $ 8,928         $ (5,840

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

5


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share data)

1. Basis of presentation:

Company

Analogic Corporation (“Analogic” or the “Company”) provides advanced healthcare and security technology solutions to customers around the world. The Company provides advanced imaging systems and technology that enable computed tomography (“CT”), ultrasound, digital mammography, and magnetic resonance imaging (“MRI”) in medical applications, as well as automated threat detection for aviation security. The Company’s CT, MRI, digital mammography, and ultrasound transducer products are sold to original equipment manufacturers (“OEMs”). The Company’s BK Medical branded ultrasound systems, used in procedure-driven markets such as urology, guided surgery, and anesthesia, are sold to clinical end users through the Company’s direct sales force. The Company’s top ten customers combined for approximately 64% of the Company’s total net revenue for the three months ended January 31, 2012 and 2011 and 65% of the Company’s total product and engineering revenue for the six months ended January 31, 2012 and 2011. The Company had three customers, as set forth in the table below, which individually accounted for 10% or more of the Company’s net product and engineering revenue during the three or six months ended January 31, 2012 or 2011.

 

     Three Months  Ended
January 31,
  Six Months Ended
January 31,
             2012                   2011                   2012                   2011        

Koninklijke Philips Electronics N.V. (“Philips”)

       15 %       10 %       15 %       12 %

Toshiba Corporation

       ( *)       13 %       11 %       12 %

Siemens AG

       11 %       10 %       11 %       ( *)

Note (*): Total net revenue was less than 10% in this period.

Philips accounted for 18% and 15% of net accounts receivable at January 31, 2012 and July 31, 2011, respectively. General Electric Corporation accounted for 13% and 12% of net accounts receivable at January 31, 2012 and July 31, 2011, respectively.

The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly owned. Investments in companies in which ownership interests range from 10% to 50%, and the Company exercises significant influence over operating and financial policies, are accounted for using the equity method. Other investments are accounted for using the cost method.

General

The unaudited consolidated financial statements of the Company presented herein have been prepared pursuant to the rules of the United States Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary for a fair statement of the results for all interim periods presented. The results of operations for the three and six months ended January 31, 2012 are not necessarily indicative of the results to be expected for the fiscal year ending July 31, 2012 (“fiscal year 2012”), or any other interim period. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended July 31, 2011 (“fiscal year 2011”) included in the Company’s Annual Report on Form 10-K as filed with the SEC on October 4, 2011. The accompanying unaudited Consolidated Balance Sheet as of July 31, 2011 contains data derived from audited financial statements.

Basis of Presentation

Certain financial statement items have been reclassified to conform to the current period presentation.

 

6


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

2. Recent accounting pronouncements:

Recently adopted

Impairment testing

In December 2010, the Financing Accounting Standards Board (the “FASB”) issued guidance modifying Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. For those reporting units, an entity is required to perform Step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists. This guidance was effective for the Company on August 1, 2011 and it did not have a material impact on its financial position, results of operations and cash flows.

In September 2011, the FASB issued an accounting standards update which provides, subject to certain conditions, the option to perform a qualitative, rather than quantitative, assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The update was effective for the Company in its first quarter of fiscal year 2012. The update did not have a material impact on its consolidated financial position, annual results of operations or cash flows.

Business combinations and noncontrolling interests

In December 2010, the FASB issued guidance specifying that if a public entity presents comparative financial statements, the entity (acquirer) should disclose revenue and earnings of the combined entity as though the business combination(s) that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. It also expands the supplemental pro forma disclosures to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and earnings. This guidance was effective for the Company prospectively for material business combinations for which the acquisition date was on or after August 1, 2011.

Not yet effective

Fair value measurements

In May 2011, the FASB issued an update to the accounting on fair value measurement to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards (“IFRS”). This update changes certain fair value measurement principles and enhances the disclosure requirements for fair value measurements. This update does not extend the use of fair value accounting, but provides guidance on how it should be applied where its use is already required or permitted by other standards within U.S. GAAP or IFRS. This update is effective for interim and annual periods beginning after December 15, 2011, and is applied prospectively. Early adoption is prohibited. This guidance is effective for the Company on February 1, 2012, and will have no impact on its financial position, results of operations, or cash flows.

Presentation of Comprehensive Income

In June 2011, the FASB issued an update to the accounting on comprehensive income to increase the prominence of items reported in other comprehensive income and to facilitate convergence of U.S. GAAP and IFRS. This update requires that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. This update does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. Further, this update does not affect how earnings per share is calculated or presented. This update is effective for annual periods beginning after December 15, 2011, and annual and interim periods thereafter. The update is applied retrospectively, and early adoption is permitted. Subsequently, in December 2011, the FASB issued guidance which defers only those changes that relate to the presentation of reclassification adjustments. This guidance is effective for the Company on August 1, 2012, and will have no impact on its financial position, results of operations, or cash flows.

 

7


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

3. Discontinued operations:

During the first quarter of fiscal year 2011, the Company sold its hotel business, and realized net proceeds of $10,467, after transaction costs. The Company recorded a gain on sale of the hotel business of $924, net of a tax provision of $505, or $0.07 per diluted share in the six months ended January 31, 2011. The hotel business has been reported as a discontinued operation and all periods presented have been revised accordingly to reflect these operations as discontinued. A former member of the Company’s Board of Directors also serves on the Board of Directors of the entity that acquired the hotel business.

Revenues and net income for the hotel business for the six months ended January 31, 2011, were as follows:

 

     Six Months Ended
January 31,

2011
    

Total net revenue

     $ 2,906  

Net income

       289  

4. Share-based compensation:

The following table presents share-based compensation expenses included in the Company’s unaudited Consolidated Statements of Operations:

 

     Three Months Ended
January 31,
   Six Months Ended
January 31,
             2012                    2011                    2012                    2011        

Cost of product sales

     $ 187        $ 164        $ 319        $ 282  

Research and product development

       905          846          1,524          1,365  

Selling and marketing

       421          371          674          574  

General and administrative

       1,637          1,389          2,884          2,331  

Share-based compensation expense before tax

     $ 3,150        $ 2,770        $ 5,401        $ 4,552  

The Company estimates the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. The Company believes that the valuation technique and the approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of the Company’s outstanding stock options granted during fiscal years 2012 and 2011. The Company estimates the fair value of restricted stock and restricted stock units based on the quoted market price of its common stock. The Company estimates the fair value of performance based restricted stock and restricted stock units with market conditions based on the use of a Monte-Carlo Simulation Model. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

The Company did not grant any stock options in the three months ended January 31, 2012 and 2011. The weighted-average grant-date fair values of stock options granted during the six months ended January 31, 2012 and 2011 were $16.36 and $15.50 per share, respectively. The fair value of each option grant was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions for the six months ended January 31, 2012 and 2011, as follows:

 

     Six Months Ended
January 31,
 
             2012                      2011          

Expected option term (1)

     5.34 years         4.74 years   

Expected volatility factor (2)

     42%         43%   

Risk-free interest rate (3)

     0.95%         1.18%   

Expected annual dividend yield (4)

     0.87%         1.00%   

 

8


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

(1) The option life was determined by estimating the expected option life using historical data.
(2) The stock volatility for each grant is determined based on the review of the weighted average of historical daily price changes of the Company’s Common Stock over the most recent five years, which approximates the expected option life of the grant.
(3) The risk-free interest rate for periods equal to the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
(4) The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.

At January 31, 2012 and January 31, 2011, the Company had target performance contingent restricted stock awards outstanding of 454,222 and 455,048, respectively. These awards, which are in the form of restricted stock shares and units, vest if specific pre-established levels of performance have been achieved at the end of a three-year performance cycle. The three year performance cycles for awards outstanding at January 31, 2012 end on July 31, 2012, 2013, and 2014. The three year performance cycles for awards outstanding at January 31, 2011 ended or will end on July 31, 2011, 2012, and 2013. The actual number of shares/units to be issued will be determined at the end of the three-year performance cycle and can range from zero to 200% of the target award. The Company grants performance awards with either an earnings per share (“EPS”) related performance condition or a total shareholder return (“TSR”) as determined against a specified peer group condition. As of January 31, 2012, of the 454,222 restricted shares/units outstanding, 252,992 had an EPS related performance condition and 201,230 had a TSR related performance condition.

For awards with a EPS-related condition, the Company recognizes compensation expense over the performance period based on the number of shares that are deemed probable of vesting at the end of the three-year performance cycle. The fair value of the awards with an EPS-related condition is determined by the closing price of the Company’s common stock on the date of grant.

For awards with a TSR-related condition, the Company recognizes compensation expense on a straight-line basis, net of estimated forfeitures, over a derived service period of 2.6 years for the awards granted in fiscal year 2012 and 2.8 years for awards granted in fiscal years 2011 and 2010. The weighted average grant date fair values of awards granted with a TSR target was $97.31 for the three and six months ended January 31, 2012. The weighted average grant date fair values of awards granted with a TSR target was $54.27 during the six months ended January 31, 2011. The fair value of awards with a TSR target at date of grant was estimated using a Monte-Carlo Simulation model with the following assumptions:

 

     Three Months Ended
January 31,

2012
  Six Months Ended
January 31,
               2012                   2011        

Stock Price (1)

     $     57.81       $   57.81       $   41.96  

Expected volatility factor (2)

       29 %       29 %       49 %

Risk-free interest rate (3)

       0.33 %       0.33 %       0.73 %

Expected annual dividend yield (4)

       0.0 %       0.0 %       0.0 %

 

(1) The stock price is the weighted average closing price of the Company’s common stock on the dates of grant.
(2) The stock volatility for each grant is determined based on the historical volatility for the peer group companies over a period equal to the remaining term of the performance period from the date of grant for all awards.
(3) The risk-free interest rate for periods equal to the performance period is based on the U.S. Treasury yield curve in effect at the time of grant.
(4) Dividends are considered reinvested when calculating TSR. For the purpose of the fair value model, the dividend yield is therefore considered to be 0%.

 

9


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

The Company recognized compensation expense on awards with performance-based and time-based conditions as follows:

 

     Three Months Ended
January 31,
   Six Months Ended
January 31,
             2012                    2011                    2012                    2011        

Performance based EPS awards

     $ 1,710        $ 980        $ 2,668        $ 1,183  

Performance based TSR awards

       802          902          1,577          1,489  

Total performance contingent restricted stock award expense

       2,512          1,882          4,245          2,672  

Time based stock options and restricted stock awards

       638          888          1,156          1,880  

Total share-based compensation expense before tax

     $ 3,150        $ 2,770        $ 5,401        $ 4,552  

The following table sets forth the stock option and restricted stock award transactions from July 31, 2011 to January 31, 2012:

 

     Stock Options Outstanding      Time-Based
Unvested  Restricted
Stock Awards
     Performance-Based
Unvested  Restricted
Stock Awards
 
     Number
of
Shares
    Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Term
(years)
     Aggregate
Intrinsic
Value
     Number
of
Shares/
Units
    Weighted
Average
Grant

Date  Fair
Value
     Number
of
Shares/
Units
(1)
    Weighted
Average
Grant

Date  Fair
Value
 

Outstanding at July 31, 2011

     274,522      $ 55.18         4.34       $ 1,466         51,800      $ 44.90         447,244      $ 46.95   

Granted

     123,226        46.06               65,239        46.44         73,348        77.56   

Exercised

     (19,157     35.08                   

Vesting of restricted stock

                (13,518     48.41         (9,665     45.98   

Cancelled (forfeited and expired)

     (28,939     46.31               (6,150     43.61         (56,705     45.86   
  

 

 

            

 

 

      

 

 

   

Outstanding at January 31, 2012

     349,652      $ 53.80         4.88       $ 2,324         97,371      $ 45.53         454,222      $ 52.05   

Options vested or expected to vest at January 31, 2012 (2)

     338,785      $ 54.06         4.83       $ 2,203             

Options exercisable at January 31, 2012

     202,334      $ 59.29         3.78       $ 690             

 

(1) The number of performance-based unvested restricted stock awards is shown in this table at target. As of January 31, 2012, the maximum number of performance-based unvested restricted stock awards available to be earned is 908,444.
(2) In addition to the vested options, the Company expects a portion of the unvested options to vest at some point in the future. Options expected to vest are calculated by applying an estimated forfeiture rate to the unvested options.

5. Business Combination

On November 19, 2010, the Company acquired certain assets of an OEM ultrasound transducer and probe business. The acquisition was undertaken by the Company in order to increase its market share in the transducer and probe business, expand its relationships with a major customer, and expand its product portfolio. The acquisition resulted in a bargain purchase as the seller was motivated to sell the assets of the transducer and probe business since they were not a core part of the seller’s business.

 

10


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

The acquisition has been accounted for as an acquisition under authoritative guidance for business combinations. The purchase price of the acquisition has been allocated to the net tangible and intangible assets acquired, with the excess of the fair value of assets acquired over the purchase price recorded as a bargain purchase gain in the three months ended January 31, 2011.

The results of operations and estimated fair value of assets acquired and liabilities assumed were included in the Company’s unaudited consolidated financial statements beginning November 19, 2010.

The total purchase consideration was expected to be approximately $686 in cash, of which approximately $346 was paid at the closing. The purchase consideration also included contingent consideration of $340, which represents the fair value of future cash payments expected to be made by the Company based on the sale of certain acquired products over a two year period commencing on November 1, 2010. The Company estimated the contingent consideration based on probability weighted expected future cash flows, and it is included under other long term liabilities in the unaudited Consolidated Balance Sheet at January 31, 2012 and July 31, 2011, respectively. These cash flows were discounted at a rate of approximately 22.1%. The contingent consideration is marked to market at the end of each fiscal quarter. During the three and six months ended January 31, 2012, the fair value of the contingent consideration was increased by $43. Acquisition-related costs were insignificant.

The final fair value allocated to each of the major classes of tangible and identifiable intangible assets acquired on November 19, 2010 and the bargain purchase gain recorded in general and administrative expenses in the unaudited Consolidated Statements of Operations were computed as follows:

 

Inventory

   $     1,284   

Property, plant, and equipment

     489   

Intangible assets

     730   

Accrued liabilities

     (154

Deferred tax liabilities

     (621
  

 

 

 

Net tangible and intangible assets

     1,728   

Estimated purchase price

     686   
  

 

 

 

Bargain purchase gain

   $ 1,042   
  

 

 

 

The deferred tax liability associated with the estimated fair value adjustments of tangible and intangible assets acquired is recorded at an estimated weighted average statutory tax rate in the jurisdictions where the fair value adjustments may occur.

The following table sets forth the components of the identifiable intangible assets acquired and being amortized over their estimated useful lives, with a maximum amortization period of five years, on a straight-line basis:

 

     Fair Value      Useful Life  

Backlog

   $ 70         3.5 months   

Developed Technology

     420         5 years   

Customer Relationships

     240         5 years   
  

 

 

    

Total acquired identifiable intangible assets

   $ 730      
  

 

 

    

In determining the purchase price allocation, the Company considered, among other factors, its intention to use the acquired assets and the historical and estimated future demand for the acquired products and services. The fair value of developed technology was based upon the relief from royalty approach while the customer relationship and backlog intangible assets were based on the income approach. The rate used to discount the estimated future net cash flows to their present values for each intangible asset was based upon a weighted average cost of capital ranging from 22.1% to 24.1%. The discount rate was determined after consideration of market rates of return on debt and equity capital, the weighted average return on invested capital and the risk associated with achieving forecasted sales related to the technology and assets acquired.

The Company’s results would not have been materially different from its reported results had the acquisition occurred at the beginning of the three and six months ended January 31, 2011.

 

11


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

6. Fair value measurements:

The Company measures the fair value of its financial assets and liabilities and non-financial assets and liabilities at least annually using a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

 

   

Level 1 – Quoted prices in active markets for identical assets or liabilities.

 

   

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

   

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s cash equivalents at January 31, 2012 and July 31, 2011 are comprised primarily of demand deposits at highly rated financial institutions.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis at January 31, 2012 and July 31, 2011:

 

     Fair Value Measurements at January 31, 2012 using     

Liabilities

   Quoted Prices in
Active Markets
for Indentical
Assets Level 1
        Significant
Other
Observable
Inputs
Level 2
        Significant
Unobservable
Inputs
Level 3
        Total
Carrying
Value

Cash equivalents

     $ —               $ 9,641             $ —               $ 9,641  

Total assets

     $ —               $ 9,641             $ —               $ 9,641  

Contingent consideration

     $ —               $ —               $ 383             $ 383  

Total liabilities

     $ —               $ —               $ 383             $ 383  
     Fair Value Measurements at July 31, 2011 using     

Liabilities

   Quoted Prices in
Active Markets
for Indentical
Assets Level 1
        Significant
Other
Observable
Inputs
Level 2
        Significant
Unobservable
Inputs
Level 3
        Total
Carrying
Value

Cash equivalents

     $ —               $ 9,600             $ —               $ 9,600  

Total assets

     $ —               $ 9,600             $ —               $ 9,600  

Contingent consideration

     $ —               $ —               $ 340             $ 340  

Total liabilities

     $ —               $ —               $ 340             $ 340  

7. Goodwill and other intangible assets:

The carrying amount of the goodwill at January 31, 2012 and July 31, 2011 was $1,849.

Other intangible assets include the value assigned to intellectual property and other technology, patents, customer contracts and relationships, a trade name, backlog, and in-process research and development. The estimated useful lives for all of these intangible assets, excluding the tradename as it is considered to have an indefinite life, are 0.5 to 14 years.

 

12


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

Intangible assets at January 31, 2012 and July 31, 2011 consisted of the following:

 

     January 31, 2012      July 31, 2011  
             Cost              Accumulated
Amortization
             Net                      Cost              Accumulated
Amortization
             Net          

Developed technology

   $ 12,191       $ 4,368       $ 7,823       $ 12,191       $ 3,762       $ 8,429   

Customer relationships

     25,440         6,899         18,541         25,440         5,973         19,467   

Tradename

     7,607         -         7,607         7,607         -         7,607   

Backlog

     70         70         -         70         70         -   

In-process research and development

     1,900         -         1,900         1,900         -         1,900   

Total

   $ 47,208       $ 11,337       $ 35,871       $ 47,208       $ 9,805       $ 37,403   

Amortization expense related to acquired intangible assets was $766 and $803 for the three months ended January 31, 2012 and 2011, respectively, and $1,532 and $1,536 for the six months ended January 31, 2012 and 2011, respectively.

The estimated future amortization expenses related to intangible assets for each of the five succeeding fiscal years is expected to be as follows:

 

2012 (remaining six months)

   $ 1,531   

2013

     3,063   

2014

     3,063   

2015

     3,063   

2016

     2,975   
  

 

 

 
   $     13,695   
  

 

 

 

In the second quarter of fiscal year 2012, the Company performed the first step of the two-step annual impairment test for its goodwill, tradename, and in-process research development. For goodwill, which is from the Company’s acquisition of Copley Controls in April 2008, the Company elected to bypass the qualitative assessment and proceeded to Step 1 of the impairment test by comparing the fair value of the OEM reporting unit in the Medical Imaging segment, to its carrying value. The Company’s approach considered both the market approach and income approach. Equal weight was given to each approach. Under the market approach, the fair value of the reporting unit is based on trading multiples. In the market approach, the Company assumed a control premium of 15% for the reporting unit, which was determined based on an analysis of control premiums for relevant recent acquisitions. Under the income approach, the fair value of the reporting unit is based on the present value of estimated future cash flows. The income approach is dependent on a number of significant management assumptions including estimates of future sales, future gross margin percentage, and discount rates. The applied discount rate of 17.1% was determined after consideration of market rates of return on debt and equity capital, the weighted average return on invested capital and the risk associated with achieving forecasted sales for the reporting unit. The Company determined that the fair value of the reporting unit was more than the carrying value of the net assets of the reporting unit, and thus it was not necessary for the Company to perform step two of the impairment test for the goodwill.

For the tradename, the Company compared the fair value of the Copley tradename using the relief from royalty approach to its carrying value during the second quarter of fiscal year 2012. The relief from royalty approach utilized a 1.3% after-tax royalty rate and a discount rate of 19.1%. The after-tax royalty rate was determined based on royalty research and margin analysis while the discount rate was determined after consideration of market rates of return on debt and equity capital, the weighted average return on invested capital and the risk associated with achieving forecasted sales for the Copley tradename. The Company determined that the fair value of the Copley tradename was more than its carrying value.

For the in-process research and development, which represents the Company’s investment of $1,900 in a start-up company with proprietary technology expected to be utilized in the Company’s Ultrasound business, the Company compared the fair value of the in-process research and development using the income approach to its carrying value during the second quarter of fiscal year 2012. The income approach utilized a discount rate of 17.1%, which was determined after consideration of market rates of return on debt and equity capital, the weighted average return on invested capital and the risk associated with achieving forecasted sales from the in-process research and development. The Company determined that the fair value of the in-process research and development was more than its carrying value.

 

13


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

Given the current economic environment and the uncertainties regarding its impact on the Company’s business, the Company’s estimates and assumptions regarding the duration of the ongoing economic downturn, or the period or strength of recovery, made for purposes of its goodwill, tradename, and in-process research and development impairment testing during the second quarter of fiscal year 2012 may not be accurate predictions of the future. If the Company’s assumptions regarding forecasted revenue or margin growth rates of the reporting unit, tradename, and in-process research and development are not achieved, the Company may be required to record an impairment charge for the goodwill, tradename, and in-process research and development in future periods, whether in connection with the Company’s next annual impairment testing in the second quarter of the fiscal year ending July 31, 2013, or prior to that if any such change constitutes a triggering event outside of the quarter from when the annual goodwill, tradename, and in-process research and development impairment test is performed. It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material.

8. Restructuring charge:

In the first quarter of fiscal year 2011, the Company recorded a restructuring charge of $3,562 for severance and personnel related costs of a plan it initiated to reduce its workforce by 104 employees worldwide. The purpose of this workforce reduction was to streamline its operations and consolidate its Denmark and Canton, Massachusetts manufacturing operations into its existing facilities. During the second quarter of fiscal year 2011, the Company recorded an adjustment of $134 for a change in estimate of severance and related benefit expenses related to this plan.

In the fourth quarter of fiscal year 2011, the Company recorded a restructuring charge of $3,585 for severance and personnel related costs of a plan to streamline its operations by reducing its workforce by 51 employees worldwide.

The following table summarizes charges related to accrued restructuring activity from July 31, 2010 through January 31, 2012:

 

     Involuntary
Employee
Severance
      Facility    
Exit Costs
  Total

Balance at July 31, 2010

     $ 153       $ 722       $ 875  

Restructuring charge

       3,562         -         3,562  

Cash payments

       (238 )       (189 )       (427 )

Foreign exchange

       42         -         42  

Balance at October 31, 2010

       3,519         533         4,052  

Adjustments

       (134 )       -         (134 )

Cash payments

       (609 )       (121 )       (730 )

Foreign exchange

       (59 )       -         (59 )

Balance at January 31, 2011

       2,717         412         3,129  

Cash payments

       (529 )       (155 )       (684 )

Foreign exchange

       156         -         156  

Balance at April 30, 2011

       2,344         257         2,601  

Restructuring charge

       3,585         -         3,585  

Adjustments

       -         53         53  

Cash payments

       (836 )       (155 )       (991 )

Foreign exchange

       (58 )       -         (58 )

Balance at July 31, 2011

       5,035         155         5,190  

Cash payments

       (1,926 )       (155 )       (2,081 )

Foreign exchange

       (93 )       -         (93 )

Balance at October 31, 2011

       3,016         -         3,016  

Cash payments

       (950 )       -         (950 )

Foreign exchange

       (113 )       -         (113 )

Balance at January 31, 2012

     $ 1,953       $ -       $ 1,953  

The cash expenditures subsequent to January 31, 2012 of approximately $1,953 in employee severance will be paid within the next six months.

 

14


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

9. Balance sheet information:

Additional information for certain balance sheet accounts is as follows for the dates indicated:

 

     January 31,
        2012         
     July 31,
        2011         
 

Accounts receivable, net of allowance:

     

Billed

   $ 72,004       $ 81,314   

Unbilled (A)

     5,960         7,244   
  

 

 

    

 

 

 
   $ 77,964       $ 88,558   
  

 

 

    

 

 

 

Inventories:

     

Raw materials

   $ 70,413       $ 75,434   

Work-in-process

     10,701         10,544   

Finished goods

     22,654         19,505   
  

 

 

    

 

 

 
   $ 103,768       $ 105,483   
  

 

 

    

 

 

 

Accrued liabilities:

     

Accrued employee compensation and benefits

   $ 17,627       $ 21,521   

Accrued restructuring charges

     1,953         5,190   

Accrued warranty

     5,767         5,174   

Other

     7,090         9,553   
  

 

 

    

 

 

 
   $ 32,437       $ 41,438   
  

 

 

    

 

 

 

Advance payments and deferred revenue:

     

Deferred revenue

   $ 8,201       $ 7,380   

Customer deposits

     2,183         1,869   
  

 

 

    

 

 

 
   $ 10,384       $ 9,249   
  

 

 

    

 

 

 

 

(A) Total unbilled receivables at January 31, 2012 and July 31, 2011 were $9,761 and $11,617, respectively. At January 31, 2012 and July 31, 2011, the long-term portion of unbilled receivables of $3,801 and $4,373, respectively, was included in non-current other assets.

 

15


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

10. Net income per share:

Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic net income per share. Diluted net income per share is computed using the sum of the weighted average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, including unvested restricted stock awards and the assumed exercise of stock options using the treasury stock method.

 

     Three Months Ended
January 31,
     Six Months Ended
January 31,
 
             2012                      2011                      2012                      2011          

Income from continuing operations

   $ 19,615       $ 5,296       $ 23,641       $ 6,677   

Income from discontinued operations, net of tax

     -         -         -         289   

Gain on disposal of discontinued operations, net of tax

     -         -         -         924   

Net income

   $ 19,615       $ 5,296       $ 23,641       $ 7,890   
           

Weighted average number of common shares outstanding-basic

     12,188,000         12,574,000         12,464,000         12,599,000   

Effect of dilutive securities:

           

Stock options and restricted stock awards

     145,000         81,000         131,000         73,000   

Weighted average number of common shares outstanding-diluted

     12,333,000         12,655,000         12,595,000         12,672,000   
           

Basic net income per share:

                                   

Income from continuing operations

   $ 1.61       $ 0.42       $ 1.90       $ 0.53   

Income from discontinued operations, net of tax

     -         -         -         0.02   

Gain on disposal of discontinued operations, net of tax

     -         -         -         0.08   

Basic net income per share

   $ 1.61       $ 0.42       $ 1.90       $ 0.63   

Diluted net income per share:

                                   

Income from continuing operations

   $ 1.59       $ 0.42       $ 1.88       $ 0.53   

Income from discontinued operations, net of tax

     -         -         -         0.02   

Gain on disposal of discontinued operations, net of tax

     -         -         -         0.07   

Diluted net income per share

   $ 1.59       $ 0.42       $ 1.88       $ 0.62   

Anti-dilutive shares related to outstanding stock options and unvested restricted stock

     239,000         207,000         253,000         228,000   

 

16


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

11. Comprehensive income:

Components of comprehensive income include net income and certain transactions that have generally been reported as a component of stockholders’ equity. The following table presents the calculation of total comprehensive income and its components:

 

     Three Months Ended
January 31,
    Six Months Ended
January 31,
 
             2012                     2011                     2012                     2011          

Net income

   $ 19,615      $ 5,296      $ 23,641      $ 7,890   

Other comprehensive income, net of taxes:

        

Pension adjustment, net of a tax benefits of $26 and $36 for the three and six months ended January 31, 2011, respectively.

     -        (46     -        (65

Foreign currency translation adjustment, net of a tax provision of $162 in the three months ended January 31, 2011 and a tax benefit of $46 in the six months ended January 31, 2011.

     (2,757     (554     (5,067     4,330   

Total comprehensive income

   $ 16,858      $ 4,696      $ 18,574      $ 12,155   

The components of accumulated other comprehensive income, net of taxes, at January 31, 2012 and July 31, 2011, were as follows:

 

     January 31,
        2012         
  July 31,
        2011         

Pension adjustment

     $ (3,079 )     $ (3,079 )

Foreign currency translation adjustment

       9,509         14,576  

Total

     $ 6,430       $ 11,497  

12. Supplemental disclosure of cash flow information:

The changes in operating assets and liabilities, net of acquired business, were as follows:

 

     Six Months Ended
January 31,
             2012                   2011        

Accounts receivable

     $ 10,105       $ (6,274 )

Inventories

       1,150         (13,655 )

Other assets

       1,378         8  

Accounts payable

       (4,652 )       12,712  

Accrued liabilities

       (6,505 )       (3,232 )

Other liabilities

       (946 )       1,540  

Advance payments and deferred revenue

       1,549         (144 )

Accrued income taxes

       (1,455 )       (245 )

Net changes in operating assets and liabilities

     $ 624       $ (9,290 )

 

17


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

Supplemental disclosure of non-cash investing activities from continuing operations were as follows:

The Company accrued milestone payments towards the construction of a manufacturing facility in Shanghai, China, of $1,015 during the six months ended January 31, 2012 that were not paid as of January 31, 2012. The Company expects to pay the $1,015 in the third quarter of fiscal year 2012.

The Company accrued milestone payments towards the building of a manufacturing facility in Shanghai, China, of $1,508 during the six months ended January 31, 2011 that were not paid as of January 31, 2011. The Company paid the $1,508 in the third quarter of fiscal year 2011.

13. Taxes:

The following table presents the provision for (benefit from) income taxes and the effective income tax rates for the three and six months ended January 31, 2012 and 2011:

 

     Three Months Ended
January 31,
  Six Months Ended
January 31,
             2012                   2011                   2012                   2011        

Provision for (benefit from) income taxes

     $ (8,869 )     $ 930       $ (7,000 )     $ 1,689  

Effective tax rate

       -83 %       15 %       -42 %       20 %

The Company received a refund of $12,007 in the second quarter of fiscal year 2012 as the result of the completion of an Internal Revenue Service (“IRS”) audit of federal income tax returns for the fiscal years ended July 31, 2003, 2005, and 2008. The refund was largely the result of Federal research and experimentation credits that carryover from the fiscal years 1991 through 2000 into the audited returns. The Company recorded a tax benefit for this refund, including the related interest, in the unaudited Consolidated Statement of Operations of $10,025 in the three and six months ended January 31, 2012. Related to the refund and interest were contingent professional fees of $2,714 that were recorded in general and administrative expenses in the unaudited Consolidated Statement of Operations in the three and six months ended January 31, 2012. In connection with the conclusion of the IRS audit, the Company recorded a benefit from the reversal and re-measurement of related tax reserves of $2,308 in the unaudited Consolidated Statement of Operations in the three and six months ended January 31, 2012.

The effective income tax rate on continuing operations is based upon the estimated income for the year, the composition of the income in different countries, and adjustments, if any, in the applicable quarterly periods for the potential tax consequences, benefits, resolutions of tax audits or other tax contingencies.

The effective tax rates for the three and six months ended January 31, 2011 of 15% and 20%, respectively, were due primarily to a discrete tax benefit of $536 for the reinstatement of the federal research and experimentation credit back to January 1, 2010 and the lower foreign tax rates as compared to the statutory rate of 35%. In addition, taxes related to the bargain purchase gain of $621 from the acquisition of an ultrasound transducer and probe business were recorded as part of income from operations.

The total amounts of gross unrecognized tax benefits, which excludes interest and penalties discussed below, were as follows for the dates indicated:

 

January 31, 2012

 

July 31, 2011

$ 6,608   $16,250

These unrecognized tax benefits, if recognized in a future period, the timing of which is not estimable, would impact the Company’s effective tax rate.

The Company is subject to U.S. Federal income tax as well as the income tax of multiple state and foreign jurisdictions. As of January 31, 2012, the Company has concluded all U.S. Federal income tax matters through the year ended July 31, 2008. In the next four quarters, the statute of limitations for the Company’s fiscal year ended July 31, 2006 may be completed for foreign subsidiaries and it is reasonably expected that net unrecognized benefits, including interest, of $203 may be recognized. During the three and six months ended January 31, 2012, the Company reduced its uncertain tax benefits and accrued interest by $11,030 as a result of the completion of the audits of fiscal years 2003, 2005 and 2008 and the re-measurement of uncertain tax benefits in open years.

The Company accrues interest and, if applicable, penalties for any uncertain tax positions. This interest and penalty expense is treated as a component of income tax expense. At January 31, 2012 and July 31, 2011, the Company had approximately $566 and $1,485, respectively, accrued for interest and penalties on unrecognized tax benefits. The decrease was due primarily to the completion of the IRS audit.

 

18


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

14. Segment information:

The Company has three reportable segments: Medical Imaging, Ultrasound, and Security Technology. At the end of fiscal year 2011, the Company combined its OEM Ultrasound transducer business, which has previously been reported in the Medical Imaging segment, with its BK Medical direct Ultrasound systems business in the Ultrasound segment, under one management team. The combined business is now reported as the Ultrasound segment consistent with how the Company’s principal executive officer began monitoring the business in the first quarter of fiscal year 2012. Medical Imaging consists primarily of electronic systems and subsystems for CT and MRI medical imaging equipment and direct conversion digital x-ray detectors for mammography sold primarily through OEM customers. Ultrasound consists of ultrasound systems and transducers for the urology, ultrasound-guided surgery and radiology markets sold primarily through the Company’s direct sales force. Security Technology consists of advanced weapon and threat detection aviation security systems and subsystems sold primarily through OEM customers. The accounting policies of the segments are the same as those described in the summary of Significant Accounting Policies included in Note 1 of the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for fiscal year 2011.

The table below presents information about the Company’s reportable segments. All periods presented have been revised accordingly to reflect the new reporting segments.

 

     Three Months Ended
January 31,
   Six Months Ended
January 31,
             2012                    2011                    2012                    2011        

Net Revenue:

                   

Medical Imaging

     $ 75,263        $ 72,842        $ 147,937        $ 137,006  

Ultrasound

       41,078          34,042          75,679          62,393  

Security Technology

       10,092          10,369          20,674          21,676  

Total

     $ 126,433        $ 117,253        $ 244,290        $ 221,075  

Income (loss) from operations

                   

Medical Imaging (A)

     $ 2,530        $ 3,503        $ 8,012        $ 5,190  

Ultrasound (B)

       4,704          2,091          4,363          1,485  

Security Technology (C)

       557          544          1,000          1,661  

Total income from operations

       7,791          6,138          13,375          8,336  

Total other income, net

       2,955          88          3,266          30  

Income from continuing operations before income taxes

     $ 10,746        $ 6,226        $ 16,641        $ 8,366  

 

     January 31,
        2012         
     July 31,
         2011        
 

Identifiable assets:

     

Medical Imaging

   $ 200,027       $ 190,530   

Ultrasound

     127,860         129,497   

Security Technology

     15,138         23,644   

Total reportable segment assets

     343,025         343,671   

Corporate assets (D)

     173,523         177,881   

Total assets

   $ 516,548       $ 521,552   

 

(A) Includes $2,198 of contingent consulting fees related to the tax refund and related interest received in the three and six months ended January 31, 2012. Includes a restructuring charge change in estimate of ($85) and $1,452 for the three and six months ended January 31, 2011, respectively.
(B) Includes restructuring charge change in estimate of ($34) and $1,548 for the three and six months ended January 31, 2011, respectively.
(C) Includes $516 of contingent consulting fees related to the tax refund and related interest received in the three and six months ended January 31, 2012. Includes a restructuring charge change in estimate of ($15) and $428 for the three and six months ended January 31, 2011, respectively.
(D) Includes cash and cash equivalents of $136,919 and $135,069 at January 31, 2012 and July 31, 2011, respectively.

 

19


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

15. Commitments and guarantees:

Guarantees and Indemnification Obligations

The Company’s standard OEM and supply agreements entered into in the ordinary course of business typically contain an indemnification provision pursuant to which the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any United States patent, or any copyright or other intellectual property infringement claim by any third party with respect to the Company’s products. Such provisions generally survive termination or expiration of the agreements. The potential amount of future payments the Company could be required to make under these indemnification provisions is, in some instances, unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes that its estimated exposure on these agreements is currently minimal. Accordingly, the Company has no liabilities recorded for these agreements as of January 31, 2012.

Generally, the Company warrants that its products will perform in all material respects in accordance with its standard published specifications in effect at the time of delivery of the products to the customer for a period ranging from 12 to 26 months from the date of delivery. The Company provides for the estimated cost of product and service warranties based on specific warranty claims, claim history, and engineering estimates, where applicable.

The following table presents the Company’s product warranty liability for the three and six months ended January 31, 2012 and 2011:

 

     Three Months Ended
January 31,
    Six Months Ended
January 31,
 
             2012                     2011                     2012                     2011          

Balance at the beginning of the period

   $ 5,250      $ 5,961      $ 5,174      $ 6,103   

Accrual

     1,867        1,702        3,829        3,094   

Settlements made in cash or in kind during the period

     (1,350     (2,023     (3,236     (3,557

Balance at the end of the period

   $ 5,767      $ 5,640      $ 5,767      $ 5,640   

At January 31, 2012 and July 31, 2011, the Company had deferred revenue for product and extended warranty contracts of $6,035 and $6,528, respectively.

Revolving Credit Agreements

On October 11, 2011, the Company entered into a five-year revolving credit agreement (“Credit Agreement”) with three banks for which Sovereign Bank acts as Administrative Agent. The Credit Agreement provides $100,000 in available credit and expires on October 10, 2016, when any outstanding borrowings will be payable in full. The credit facility does not require amortization of principal and may be reduced before maturity in whole or in part at the Company’s option without penalty. The Credit Agreement replaces a $20,000 credit facility with Sovereign Bank which had been renewed annually since 2001 and was terminated in connection with the new facility.

Borrowings under the Credit Agreement may be used for general corporate purposes, including permitted acquisitions. The amount of available credit can be increased under specified circumstances up to $150,000 in aggregate. The Company is the sole borrower under the Credit Agreement. The obligations under the new credit facility are guaranteed by the Company’s material domestic subsidiaries and are supported by a pledge of 65% of the capital stock and equity equivalents of the Company’s principal international subsidiary.

Interest rates on borrowings outstanding under the credit facility would range from 1.25% to 2.00% above the LIBOR rate, or, at the Company’s option would range from 0.00% to 1.00% above the defined base rate, in each case based upon the Company’s leverage ratio. A quarterly commitment fee ranging from 0.20% to 0.35% per annum is applicable on the undrawn portion of the credit facility, based upon the Company’s leverage ratio.

 

20


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

The Credit Agreement limits the Company and its subsidiaries’ ability to, among other things: incur additional indebtedness; incur liens or guarantee obligations; pay dividends or make other distributions; make investments; dispose of assets; and engage in transactions with affiliates except on an arms-length basis. In addition, the Credit Agreement requires the Company to maintain the following financial ratios:

 

   

A leverage ratio, defined as consolidated funded indebtedness to consolidated trailing four quarters EBITDA of no greater than 2.75:1.00 at any time; and

 

   

An interest coverage ratio, defined as the ratio of consolidated trailing four quarters EBITDA to consolidated interest charges of no less than 3.00:1.00 at any time.

At January 31, 2012, the Company’s leverage ratio was 0.004 and the Company’s interest coverage ratio was infinite as it had no attributable interest expense. As of January 31, 2012, the Company was in full compliance with all financial and operating covenants.

Any failure to comply with the financial or operating covenants of the credit facility would prevent the Company from being able to borrow and would also constitute a default, permitting the lenders to, among other things, accelerate repayment of outstanding borrowings, including all accrued interest and fees, and to terminate the credit facility. A change in control of the Company, as defined in the Credit Agreement, would also constitute an event of default, permitting the lenders to accelerate repayment and terminate the Credit Agreement.

In connection with the entering into this facility, the Company incurred approximately $500 of transactions costs, which are being expensed over the five-year life of the credit facility.

The Company currently has approximately $104,000 in revolving credit facilities with banks available for direct borrowings. The Company did not have any borrowing outstanding under credit facilities at January 31, 2012 and July 31, 2011.

Investigation Regarding our Danish Subsidiary

As previously disclosed in the Company’s annual report on Form 10-K for the fiscal year ended July 31, 2011, the Company has identified transactions involving its Danish subsidiary, BK Medical, and certain of its foreign distributors, with respect to which the Company has raised questions concerning compliance with law, including Danish law and the United States Foreign Corrupt Practices Act, and its business policies. The Company has voluntarily disclosed this matter to the Danish government, the United States Department of Justice, and the Securities and Exchange Commission and will continue to cooperate with the relevant authorities regarding these matters. The Company is unable to estimate the potential penalties and/or sanctions, if any, that might be assessed in connection with this matter. The Company has concluded that the identified transactions have been properly accounted for in its reported financial statements in all material respects. The Company has terminated the employment of BK Medical employees that were involved in the transactions. The Company is winding down its relationship with BK Medical distributors that were involved in the transactions. Replacing these employees and distributors could have an adverse impact on BK Medical’s distributor sales until their replacements are in place and productive. Revenue from sales to the BK Medical distributors with whom the Company has decided to wind down BK Medical’s relationship, represented less than 1% of the Company’s total revenue in fiscal year 2011 and less than 2.5% of the Company’s total revenue in the three and six months ended January 31, 2012. During the six months ended January 31, 2012, the Company incurred employee termination costs of approximately $400 and inquiry-related costs of approximately $1,204 in connection with this matter.

16. Common stock repurchases:

On December 9, 2010, the Company announced that its Board of Directors had authorized the repurchase of up to $30,000 of the Company’s common stock. The repurchase program was funded using the Company’s available cash. During the three and six months ended January 31, 2012, the Company repurchased and retired 54,690 and 286,390 shares of Common Stock, respectively, under this repurchase program for $3,005 and $14,813, respectively, at an average purchase price of $54.95 and $51.73 per share, respectively. Upon completion of the program in the second quarter of fiscal year 2012, the Company ultimately repurchased and retired 586,679 shares of Common Stock for $30,000 at an average purchase price of $51.14 per share.

On December 8, 2011, the Company announced that its Board of Directors had authorized the repurchase of up to an additional $30,000 of the Company’s common stock. The repurchase program will be funded using the Company’s available cash. During the three and six months ended January 31, 2012, the Company repurchased and retired 14,732 shares of Common Stock under this repurchase program for $799 at an average purchase price of $54.25 per share.

 

21


Table of Contents

ANALOGIC CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

 

17. Related party transactions:

On July 25, 2011, the Company entered into an agreement to sell its 25% interest in its China-based affiliate for $2,500. The book value of the interest in the China-based affiliate was written down to $0 in fiscal year 2006, and the Company, upon final approval of the transaction by the Chinese government and receipt of the proceeds, recorded a gain on sale of other investments of $2,500 in the three and six months ended January 31, 2012.

At January 31, 2012, the Company had no accounts receivable outstanding or any deferred revenue or advanced payments from its China-based affiliate. At July 31, 2011, the Company had a net advance payments and deferred revenue balance of $474 from its China-based affiliate. Sales to this China-based affiliate for the three and six months ended January 31, 2012 were $507 and $1,570, respectively. Sales to this China-based affiliate for the three and six months ended January 31, 2011 were $895 and $998, respectively.

18. Subsequent event:

The Company declared a dividend of $0.10 per share of common stock on March 1, 2012, which will be paid on March 29, 2012 to stockholders of record on March 19, 2012.

 

22


Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion provides an analysis of our financial condition and results of operations and should be read in conjunction with the unaudited Consolidated Financial Statements and Notes thereto included elsewhere in this report. The discussion contains statements, which, to the extent that they are not a recitation of historical facts, constitute “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements about product development, market and industry trends, strategic initiatives, regulatory approvals, sales, profits, expenses, price trends, research and development expenses and trends, and capital expenditures, we make in this document or in any document incorporated by reference are forward-looking. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause our actual results, performance, or achievements to differ from the projected results. See “Risk Factors” in Part I, Item 1A. of our Annual Report on Form 10-K for fiscal year 2011 as filed with the U.S Securities and Exchange Commission (the “SEC”) on October 4, 2011 for a discussion of the primary risks and uncertainties known to us.

We report our financial condition and results of operations on a fiscal year basis ending July 31. The three months ended January 31, 2012 and 2011 represent the second quarters of fiscal years 2012 and 2011, respectively. All dollar amounts in this Item 2 are in thousands except per share data.

Summary

Analogic provides advanced healthcare and security technology solutions to customers around the world. We provide advanced imaging systems and technology that enable computed tomography (“CT”), ultrasound, digital mammography, and magnetic resonance imaging (“MRI”) in medical applications, as well as automated threat detection for aviation security. Our CT, MRI, digital mammography, and ultrasound transducer products are sold to original equipment manufacturers (“OEMs”). Our BK Medical branded ultrasound systems, used in procedure-driven markets such as urology, guided surgery, and anesthesia, are sold to clinical end users through our direct sales force.

We have three reportable segments: Medical Imaging, Ultrasound, and Security Technology. At the end of fiscal year 2011, we combined our OEM Ultrasound transducer business, which has previously been reported in the Medical Imaging segment, and our BK Medical direct Ultrasound systems business in the Ultrasound segment, under one management team. The combined business is now reported as the Ultrasound segment consistent with how our principal executive officer began monitoring the business in the first quarter of fiscal year 2012. All periods presented have been revised accordingly to reflect the new reporting segments.

The following table sets forth the percentage of total net revenue by reporting segment for the three months ended January 31, 2012 and 2011.

 

     Three Months Ended
January 31,
             2012                   2011        

Medical Imaging

       60 %       62 %

Ultrasound

       32 %       29 %

Security Technology

       8 %       9 %

Total

       100 %       100 %

A significant portion of our products are sold to OEMs, whose purchasing dynamics have an impact on our reported sales. OEMs that purchase our Medical Imaging products generally incorporate those products as components in their systems, which are in turn sold to end users, primarily hospitals and medical clinics. In our Security Technology business, OEM customers purchase and resell our products to end users including domestic and foreign airports as well as the U.S Transportation Security Administration or TSA. In Security Technology, our OEM customers’ purchasing dynamics are affected by the level of government funding, the expansion of airport terminals and fluctuations in airline passenger volume.

 

23


Table of Contents

The following table sets forth key financial data from our unaudited Consolidated Statements of Operations for the three months ended January 31, 2012 and 2011.

 

     Three Months Ended
January 31,
  Percentage
Change
             2012                   2011          

Total net revenue

     $ 126,433       $ 117,253         8 %

Gross profit

     $ 46,845       $ 40,809         15 %

Gross margin

       37 %       35 %    

Income from operations

     $ 7,791       $ 6,138         27 %

Operating margin percentage

       6 %       5 %    

Income from continuing operations

     $ 19,615       $ 5,296         270 %

Diluted net income per share from continuing operations

     $ 1.59       $ 0.42         279 %

During the three months ended January 31, 2012 our total net revenue increased by 8% as compared to the prior year comparable period due primarily to a 21% increase in revenues in our Ultrasound segment reflecting increased sales of our Flex Focus platform of products in the United States through our expanded sales force and internationally primarily through our distributor network. Revenue also increased 3% in our Medical Imaging segment as a result of increased demand in our MRI and digital mammography product lines, offset by a reduction in shipments of CT components due to customer ordering patterns. Product revenues in our Security business increased 15%, but were offset by lower engineering revenues as we completed development on key projects.

Gross margin increased in the three months ended January 31, 2012 versus the prior year comparable period due primarily to an improved mix of higher margin Ultrasound products as well as the benefit of our manufacturing consolidation efforts completed by the end of fiscal year 2011.

Income from operations increased in the three months ended January 31, 2012 from the prior year comparable period due primarily to increased gross profit from an increase in sales volumes and headcount reductions made in fiscal year 2011. Included in income from operations in the three months ended January 31, 2011 was the favorable impact of an acquisition bargain purchase gain included in general and administrative expenses of $1,042, offset in part by $386 of amortization for the intangible assets and inventory fair value adjustment associated with this acquisition.

During the second quarter of fiscal year 2012, we received a refund of $12,007 as the result of the completion of an Internal Revenue Service (“IRS”) audit of federal income tax returns for the fiscal years ended July 31, 2003, 2005, and 2008. The refund was largely the result of Federal research and experimentation credits that carryover from the fiscal years 1991 through 2000 into the audited returns. We recorded a tax benefit for this refund, including the related interest, in the unaudited Consolidated Statement of Operations of $10,025 in the three and six months ended January 31, 2012. The tax benefit from the refund and interest were partially offset by related contingent professional fees of $2,714 recorded in general and administrative expenses within income from operations in the unaudited Consolidated Statement of Operations in the three and six months ended January 31, 2012. In connection with the conclusion of the IRS audit, the Company recorded a reversal and re-measurement of related tax reserves of $2,308 in the unaudited Consolidated Statement of Operations in the three and six months ended January 31, 2012.

In addition to the positive impact from the growth in income from operations and the tax benefit of $10,025, income from continuing operations and diluted net income per share from continuing operations in the three months ended January 31, 2012 were favorably impacted by a gain of $2,500 on the sale of our remaining ownership interest of 25% in our China-based affiliate.

During the first quarter of fiscal year 2011, we sold our hotel business, and realized net proceeds of $10,467, after transaction costs for this sale. We recorded a gain on the sale of the hotel business of $924, net of a tax provision of $505, or $0.07 per diluted share, in the three months ended October 31, 2010. The hotel business is being reported as a discontinued operation and all periods presented have been revised accordingly to reflect these operations as discontinued.

Net revenue and net income for the hotel business for the six months ended January 31, 2011 was as follows:

 

     Six Months
Ended January 31,
2011
 

Total net revenue

   $     2,906   

Net income

     289   

 

24


Table of Contents

The following table sets forth an overview of cash flows for the six months ended January 31, 2012 and 2011.

 

     Six Months
Ended January 31,
 
             2012                     2011          

Net cash provided by continuing operations for operating activities

   $ 38,823      $ 7,548   

Net cash used for investing activities

     (14,750     (1,804

Net cash used for financing activities

     (17,754     (13,577

Net cash used for discontinued operations

     -        (335

Effect of exchange rate changes on cash

     (1,669     1,509   

Net increase (decrease) in cash and cash equivalents

   $ 4,650      $ (6,659

During the six months ended January 31, 2012, we generated $38,823 of cash from operating activities of continuing operations as compared to $7,548 in the prior year comparable period. The increase was due primarily to an increase in sales volume and improved operating efficiency in the six months ended January 31, 2012 as compared to the prior year comparable period as well as an income tax refund and related interest received in the six months ended January 31, 2012 of $12,007. Net cash used by continuing operations for investing activities in the six months ended January 31, 2012 was due primarily to capital spending of $17,278, which includes the construction of a manufacturing facility in Shanghai, China, and the purchase of a facility in State College, Pennsylvania. Prior year cash used by continuing operations for investing activities in the six months ended January 31, 2011 was due primarily to capital spending of $12,048, which includes the construction of a manufacturing facility in Shanghai, China. This was partially offset by the proceeds from the sale of our hotel business of $10,467, after transaction costs. The net cash used by financing activities in the six months ended January 31, 2012 and 2011 primarily reflected cash used to repurchase common stock of $15,612 and $11,149, respectively.

Results of operations

Net revenue

Product revenue

Product revenue is summarized in the table below.

 

     Three Months Ended
January 31,
       Percentage    
Change
  Six Months Ended
January 31,
       Percentage    
Change
             2012                    2011                      2012                    2011           

Product Revenue:

                            

Medical Imaging

     $ 73,234        $ 70,526          4 %     $ 143,534        $ 132,116          9 %

Ultrasound

       41,078          33,918          21 %       75,679          62,269          22 %

Security Technology

       7,877          6,871          15 %       16,983          13,619          25 %

Total

     $ 122,189        $ 111,315          10 %     $ 236,196        $ 208,004          14 %

Medical Imaging

For the three and six months ended January 31, 2012, product revenue increased versus the prior year comparable periods primarily due to growth in our MRI and digital mammography product lines driven primarily by higher sales volume of new and existing products, partially offset by a reduction in shipments in our CT product line due to customer ordering patterns.

Ultrasound

For the three and six months ended January 31, 2012, product revenue increased versus the prior year comparable periods due to increased sales of our Flex Focus platform of products in the United States through our expanded sales force and internationally primarily through our distributor network, as well as increased demand for ultrasound transducers sold through OEMs. Also contributing to the increase in product revenue in the six months ended January 31, 2012 was the acquisition of an OEM ultrasound transducer business in second quarter of fiscal year 2011.

Security Technology

The increase in product revenues for the three and six months ended January 31, 2012 versus the prior year comparable period was due primarily to increased sales of baggage scanners due to increasing demand from a large OEM customer.

 

25


Table of Contents

Engineering revenue

Engineering revenue is summarized in the table below.

 

     Three Months Ended
January 31,
         Percentage    
Change
    Six Months Ended
January 31,
         Percentage    
Change
 
             2012                      2011                        2012                      2011             

Engineering Revenue:

                

Medical Imaging

   $ 2,029       $ 2,316         -12   $ 4,403       $ 4,890         -10

Ultrasound

     -         124         N/A        -         124         N/A   

Security Technology

     2,215         3,498         -37     3,691         8,057         -54

Total

   $ 4,244       $ 5,938         -29   $ 8,094       $ 13,071         -38

Medical Imaging

The decreases for the three and six months ended January 31, 2012 versus the prior year comparable periods were due primarily to the timing of project milestones being completed.

Security Technology

The decrease for the three and six months ended January 31, 2012 versus the prior year comparable period was due primarily to the timing of work performed on a significant development project for a large OEM customer.

Gross margin

Product gross margin

Product gross margin is summarized in the table below.

 

     Three Months Ended
January 31,
        Percentage    
Change
    Six Months Ended
January 31,
        Percentage    
Change
 
             2012                     2011                       2012                     2011            

Product gross profit

   $ 46,484      $ 40,719        14.2   $ 89,260      $ 78,352        13.9

Product gross margin %

     38.0     36.6       37.8     37.7  

Product gross margin percentage increased in the three and six months ended January 31, 2012 versus the prior year comparable periods reflecting an improved mix of higher margin Ultrasound products as well as cost savings following consolidation of our manufacturing operations in fiscal year 2011. Partially offsetting these increases were unfavorable manufacturing yields in our digital mammography business and inventory write offs upon closure of our Denmark manufacturing operation.

Engineering gross margin

Engineering gross margin is summarized in the table below.

 

     Three Months Ended
January 31,
      Percentage    
Change
  Six Months Ended
January 31,
      Percentage    
Change
             2012                   2011                     2012                   2011          

Engineering gross profit

     $ 361       $ 90         301.1 %     $ 611       $ 1,476         -58.6 %

Engineering gross margin %

       8.5 %       1.5 %           7.5 %       11.3 %    

The increase in engineering gross margin in the three months ended January 31, 2012 versus the prior year comparable period was due primarily to a decrease of loss contracts for Medical Imaging projects.

The decrease in engineering gross margin in the six months ended January 31, 2012 versus the prior year comparable period was due primarily to less work performed on higher margin generating Security Technology engineering projects.

 

26


Table of Contents

Operating expenses

Operating expenses are summarized in the table below.

 

     Three Months Ended
January 31,
  Six Months Ended
January 31,
             2012                    2011                   2012                    2011        

Research and product development

     $ 13,940        $ 14,769       $ 29,207        $ 28,673  

Selling and marketing

       10,605          10,716         21,070          20,324  

General and administrative

       14,509          9,320         26,219          19,067  

Restructuring

       -          (134 )       -          3,428  

Total operating expenses

     $ 39,054        $ 34,671       $ 76,496        $ 71,492  

Operating expenses as a percentage of total net revenue are summarized in the table below.

 

     Three Months Ended
January 31,
  Six Months Ended
January 31,
             2012                   2011                   2012                   2011        

Research and product development

       11.0 %       12.6 %       12.0 %       12.9 %

Selling and marketing

       8.4 %       9.1 %       8.6 %       9.2 %

General and administrative

       11.5 %       8.0 %       10.7 %       8.6 %

Restructuring

       0.0 %       -0.1 %       0.0 %       1.6 %

Total operating expenses

       30.9 %       29.6 %       31.3 %       32.3 %

Research and product development costs included in operating expenses are related to projects not funded by our customers. These expenses decreased $829 and increased $534 in the three and six months ended January 31, 2012, respectively, versus the prior year comparable periods. The decrease in the three months ended January 31, 2012 was due primarily to cost savings from work force reductions made throughout fiscal year 2011. The increase in the six months ended January 31, 2012 was due primarily to greater investment in unfunded research and product development projects in support of our strategic growth initiatives.

Selling and marketing expenses decreased $111 and increased $746 in the three and six months ended January 31, 2012, respectively, versus the prior year comparable periods. The increase in the six months ended January 31, 2012 was due primarily to severance costs of approximately $400 for employees terminated in connection with certain distributor transactions involving BK Medical. Also contributing to the increase in the six months ended January 31, 2012 was an increase in selling resources in the Ultrasound business as we expand our sales force and product offerings in existing and adjacent markets.

General and administrative expenses increased $5,189 and $7,152 in the three and six months ended January 31, 2012, respectively, versus the prior year comparable periods, primarily due to the impact of contingent consulting fees of $2,714 in the three and six months ended January 31, 2012 related to the income tax refund and related interest received in that period, as well as the favorable impact in the three and six months ended January 31, 2011 of an acquisition bargain purchase gain included in general and administrative expenses of $1,042, offset in part by $386 of amortization for the intangible assets and inventory fair value adjustment associated with this acquisition. The increase in expenses also reflects inquiry costs of $207 and $1,204 in the three and six months ended January 31, 2012, respectively, related to a distributor matter at BK Medical, our Danish subsidiary.

Restructuring in the six months ended January 31, 2011 included severance and personnel related costs for our plan that resulted in the reduction of our headcount by 104 employees worldwide.

 

27


Table of Contents

Other income (expense), net

Other income (expense), net is summarized in the table below.

 

     Three Months Ended
January 31,
  Six Months Ended
January 31,
             2012                    2011                   2012                    2011        

Interest income, net

     $ 133        $ 188       $ 269        $ 406  

Gain on sale of other investments

     $ 2,500        $ -       $ 2,500        $ -  

Other, net

     $ 322        $ (100 )     $ 497        $ (376 )

The gain on sale of other investments for the three and six months ended January 31, 2012 was due primarily to $2,500 from the sale of our 25% equity interest in our China-based affiliate. The book value of this investment was written down to $0 in fiscal year 2006.

Net other income (expense) during the three and six months ended January 31, 2012 and 2011 consisted predominantly of foreign currency exchange losses by our foreign subsidiaries in Denmark and Canada.

Provision for income taxes

The provision for (benefit from) income taxes and the effective tax rates are summarized in the table below.

 

     Three Months Ended
January 31,
  Six Months Ended
January 31,
             2012                   2011                   2012                   2011        

Provision for (benefit from) income taxes

     $ (8,869 )     $ 930       $ (7,000 )     $ 1,689  

Effective tax rate

       -83 %       15 %       -42 %       20 %

Our effective income tax rate on continuing operations is based upon the estimated income for the year, the composition of the income in different countries, and adjustments, if any, in the applicable quarterly periods for the potential tax consequences, benefits, resolutions of tax audits or other tax contingencies.

For the three and six months ended January 31, 2012, our income tax benefits of $8,869 and $7,000, respectively, were due primarily to discrete tax benefits of $10,025 from the refund of Federal research and experimentation credits and related interest and the $2,308 reversal and re-measurement of related tax reserves. In the next four quarters, the statute of limitations for fiscal year ended July 31, 2006 may be completed for foreign subsidiaries, and it is reasonably expected that net unrecognized benefits, including interest, of $203 may be recognized.

For the three and six months ended January 31, 2011, the effective tax rate benefited from a discrete tax benefit of $536 for the reinstatement of the federal research and experimentation credit back to January 1, 2010 and the lower foreign tax rates as compared to the statutory rate of 35%. In addition, taxes related to the bargain purchase gain of $621 from the acquisition of an ultrasound transducer and probe business were recorded as part of income from operations.

Income from discontinued operations, net of tax

 

     Six Months Ended
January 31,
 
             2012                      2011          

Income from discontinued operations, net of tax

   $     -       $ 289   

During the first quarter of fiscal year 2011, we sold our hotel business.

 

28


Table of Contents

Income from continuing operations and diluted net income per share from continuing operations

Income from continuing operations and diluted net income per share from continuing operations for the three and six months ended January 31, 2012 and 2011 are as follows:

 

     Three Months Ended
January 31,
    Six Months Ended
January 31,
 
             2012                     2011                     2012                     2011          

Income from continuing operations

   $ 19,615      $ 5,296      $ 23,641      $ 6,677   

% of net revenue

     15.5     4.5     9.7     3.0

Diluted net income per share from continuing operations

   $ 1.59      $ 0.42      $ 1.88      $ 0.53   

The increase in income from continuing operations and diluted net income per share from continuing operations for the three and six months ended January 31, 2012 versus the prior year comparable periods were due primarily to increased gross profit from an increase in sales volume, cost savings following consolidation of our manufacturing operations, cost savings from other operational headcount reductions in fiscal year 2011, an income tax benefit from a refund and related interest, a gain on sale of an equity interest, and a decrease in restructuring charges in the three and six months ended January 31, 2012, partially offset by contingent consulting fees related to the tax refund in the three and six months ended January 31, 2012 and the bargain purchase gain in the three and six months ended January 31, 2011 of $1,042. Also offsetting these increases were inquiry costs related to a distributor matter at BK Medical of $1,204 in the six months ended January 31, 2012.

Liquidity and capital resources

Key liquidity and capital resource information is summarized in the table below.

 

     January 31,
        2012         
     July 31,
        2011         
 

Cash and cash equivalents

   $ 174,306       $ 169,656   

Working capital

     293,420         294,387   

Short and long term debt

     -         -   

Stockholders’ equity

     431,558         423,472   

Cash and cash equivalents at January 31, 2012 consisted entirely of highly liquid investments with maturities of three months or less from the time of purchase. We periodically review our investment portfolio to determine if any investments are impaired due to changes in credit risk or other potential valuation concerns. We believe that our cash equivalents were appropriately valued at January 31, 2012 and we are not aware of any market events that would impact their valuation. This could change in the future should new developments arise in the credit markets.

The carrying amounts reflected in the consolidated balance sheets of cash and cash equivalents, trade receivables, and trade payables approximate fair value at January 31, 2012, due to the short maturities of these instruments.

We face exposure to financial market risks, including adverse movements in foreign currency exchange rates, and to a lesser extent changes in interest rates. These exposures can change over time as business practices evolve and could have a material adverse impact on our financial results. Our primary exposure is related to fluctuations between the U.S. dollar and local currencies for our subsidiaries in Canada, Europe, and China. Our investment in international subsidiaries is sensitive to fluctuations in currency exchange rates. The effect of a change in currency exchange rates on our net investment in international subsidiaries is reflected in the “accumulated other comprehensive income” component of stockholders’ equity. A 10% devaluation in the January 31, 2012 and July 31, 2011 functional currencies, relative to the U.S. dollar, would result in a reduction of stockholders’ equity of approximately $950 and $1,458, respectively.

Cash flows

The following table summarizes our sources and uses of cash over the periods indicated:

 

     Six Months Ended
January 31,
 
             2012                     2011          

Net cash provided by continuing operations for operating activities

   $ 38,823      $ 7,548   

Net cash used for investing activities

     (14,750     (1,804

Net cash used for financing activities

     (17,754     (13,577

Net cash used for discontinued operations

     -        (335

Effect of exchange rate changes on cash

     (1,669     1,509   

Net increase (decrease) in cash and cash equivalents

   $ 4,650      $ (6,659

 

29


Table of Contents

The cash flows generated from operating activities of our continuing operations in the six months ended January 31, 2012 primarily reflects our pre-tax earnings from continuing operations of $16,641, which included depreciation and amortization expenses of $9,205 and non-cash share-based compensation expense of $5,401. Also contributing to the increase were a tax refund of $12,007 and a decrease in accounts receivable of $10,105. The positive impact of our operating earnings on cash flows was partially offset by decreases in accrued liabilities and accounts payable of $6,505 and $4,652, respectively. The decrease in accounts receivable was due primarily to improved collections and a decrease in unbilled receivables of approximately $2,000 on engineering projects due to the timing of completing milestones. The decrease in accrued liabilities was due primarily to the payment of bonuses and severance partially offset by additional bonus accrual for fiscal year 2012. The decrease in accounts payable was due primarily to the timing of vendor payments.

The net cash used by continuing operations for investing activities in the six months ended January 31, 2012 was due primarily to purchases of property, plant, and equipment of $17,278, of which approximately $12,000 relates to the construction of a manufacturing facility in Shanghai, China and the purchase of a facility in State College, Pennsylvania. The capital spending was partially offset by the proceeds of $2,500 received from the sale of our 25% equity interest in our China-based affiliate during the second quarter of fiscal year 2012.

The net cash used for financing activities in the six months ended January 31, 2012 primarily reflected $15,612 used to repurchase common stock and $2,609 of dividends paid to stockholders.

We believe that our balances of cash and cash equivalents and cash flows expected to be generated by future operating activities will be sufficient to meet our cash requirements for at least the next 12 months.

Commitments, contractual obligations, and off-balance sheet arrangements

Our contractual obligations at January 31, 2012, and the effect such obligations are expected to have on liquidity and cash flows in future periods, are as follows:

 

Contractual Obligation            Total              Less than
        1 year         
     1 - 3
        years        
     More than
3 years  -

      5 years      
     More than
       5 years      
 

Operating leases

   $ 8,725       $ 2,191       $ 2,875       $ 1,639       $ 2,020   

Purchasing obligations

     61,690         58,674         3,016         -         -   
  

 

 

 
   $ 70,415       $ 60,865       $ 5,891       $ 1,639       $ 2,020   
  

 

 

 

As of January 31, 2012, the total liabilities associated with uncertain tax positions were $6,608. Due to the complexity associated with our tax uncertainties, we cannot make a reasonably reliable estimate of the period in which we expect to settle the non-current liabilities associated with these uncertain tax positions. Therefore, these amounts have not been included in the contractual obligations table.

On October 11, 2011, we entered into a five-year revolving credit agreement (the “Credit Agreement”) with three banks for which Sovereign Bank acts as Administrative Agent. The Credit Agreement provides $100,000 in available credit and expires on October 10, 2016, when any outstanding borrowings will be payable in full. The credit facility does not require amortization of principal and may be reduced before maturity in whole or in part at our option without penalty. The Credit Agreement replaces a $20,000 credit facility with Sovereign Bank which had been renewed annually since 2001 and was terminated in connection with the new facility.

Borrowings under the Credit Agreement may be used for general corporate purposes, including permitted acquisitions. The amount of available credit can be increased under specified circumstances up to $150,000 in aggregate. We are the sole borrower under the Credit Agreement. The obligations under the new credit facility are guaranteed by our material domestic subsidiaries and are supported by a pledge of 65% of the capital stock and equity equivalents of our principal international subsidiary.

Interest rates on borrowings outstanding under the credit facility would range from 1.25% to 2.00% above the LIBOR rate, or, at our option would range from 0.00% to 1.00% above the defined base rate, in each case based upon our leverage ratio. A quarterly commitment fee ranging from 0.20% to 0.35% per annum is applicable on the undrawn portion of the credit facility, based upon our leverage ratio.

The Credit Agreement limits us and our subsidiaries’ ability to, among other things: incur additional indebtedness; incur liens or guarantee obligations; pay dividends or make other distributions; make investments; dispose of assets; and engage in transactions with affiliates except on an arms-length basis. In addition, the Credit Agreement requires us to maintain the following financial ratios:

 

   

A leverage ratio, defined as consolidated funded indebtedness to consolidated trailing four quarters EBITDA of no greater than 2.75:1.00 at any time; and

 

30


Table of Contents
   

An interest coverage ratio, defined as the ratio of consolidated trailing four quarters EBITDA to consolidated interest charges of no less than 3.00:1.00 at any time.

At January 31, 2012, our leverage ratio was 0.004 and our interest coverage ratio was infinite as we had no attributable interest expense, and we were in full compliance with all financial and operating covenants.

Any failure to comply with the financial or operating covenants of the credit facility would prevent us from being able to borrow and would also constitute a default, permitting the lenders to, among other things, accelerate repayment of outstanding borrowings, including all accrued interest and fees, and to terminate the credit facility. A change in control of Analogic Corporation, as defined in the Credit Agreement, would also constitute an event of default, permitting the lenders to accelerate repayment and terminate the Credit Agreement.

In connection with the entering into this facility, we incurred approximately $500 of transactions costs, which are being expensed over the five-year life of the credit facility.

We currently also have approximately $4,000 in other revolving credit facilities with banks available for direct borrowings.

We did not have any borrowing outstanding under credit facilities at January 31, 2012 and July 31, 2011.

Impact of Investigation Regarding our Danish Subsidiary

As previously disclosed in our annual report on Form 10-K for the fiscal year ended July 31, 2011, we have identified transactions involving our Danish subsidiary, BK Medical, and certain of its foreign distributors, with respect to which we have raised questions concerning compliance with law, including Danish law and the United States Foreign Corrupt Practices Act, and our business policies. We have voluntarily disclosed this matter to the Danish government, the United States Department of Justice and the Securities and Exchange Commission and will continue to cooperate with relevant authorities regarding these matters. We are unable to estimate the potential penalties and/or sanctions, if any, that might be assessed in connection with this matter. We have concluded that the identified transactions have been properly accounted for in our reported financial statements in all material respects. We have terminated the employment of BK Medical employees that were involved in the transactions. We are winding down our relationship with BK Medical distributors that were involved in the transactions. Replacing these employees and distributors could have an adverse impact on BK Medical’s distributor sales until their replacements are in place and productive. Revenue from sales to the BK Medical distributors with whom we have decided to wind down BK Medical’s relationship, represented less than 1% of our total revenue in fiscal year 2011 and less than 2.5% of our total revenue in the three and six months ended January 31, 2012. During the six months ended January 31, 2012, we incurred employee termination costs of approximately $400 and inquiry-related costs of approximately $1,204 in connection with this matter.

Recent accounting pronouncements

Recently adopted

Impairment testing

In December 2010, the Financing Accounting Standards Board (the “FASB”) issued guidance modifying Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. For those reporting units, an entity is required to perform Step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists. This guidance was effective for us on August 1, 2011 and it did not have a material impact on our financial position, results of operations, or cash flows.

In September 2011, the FASB issued an accounting standards update which provides, subject to certain conditions, the option to perform a qualitative, rather than quantitative, assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The update was effective for us in the second quarter of fiscal year 2012. The update may did not have a material impact on our consolidated financial position, annual results of operations or cash flows.

Business combinations and noncontrolling interests

In December 2010, the FASB issued guidance specifying that if a public entity presents comparative financial statements, the entity (acquirer) should disclose revenue and earnings of the combined entity as though the business combination(s) that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. It also expands the supplemental pro forma disclosures to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and earnings. This guidance was effective for us prospectively for material business combinations for which the acquisition date is on or after August 1, 2011.

 

31


Table of Contents

Not yet effective

Fair value measurements

In May 2011, the FASB issued an update to the accounting on fair value measurement to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards (“IFRS”). This update changes certain fair value measurement principles and enhances the disclosure requirements for fair value measurements. This update does not extend the use of fair value accounting, but provides guidance on how it should be applied where its use is already required or permitted by other standards within U.S. GAAP or IFRS. This update is effective for interim and annual periods beginning after December 15, 2011, and is applied prospectively. Early adoption is prohibited. This guidance is effective for us on February 1, 2012, and and will have no impact on our financial position, results of operations, or cash flows.

Presentation of Comprehensive Income

In June 2011, the FASB issued an update to the accounting on comprehensive income to increase the prominence of items reported in other comprehensive income and to facilitate convergence of U.S. GAAP and IFRS. This update requires that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. This update does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. Further, this update does not affect how earnings per share is calculated or presented. This update is effective for annual periods beginning after December 15, 2011, and annual and interim periods thereafter. The update is applied retrospectively, and early adoption is permitted. Early adoption is permitted. Subsequently, in December 2011, the FASB issued guidance which defers only those changes that relate to the presentation of reclassification adjustments. This guidance is effective for us on August 1, 2012, and it is not expected to have a material impact on our financial position, results of operations, or cash flows.

Critical accounting policies

The accompanying discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. Our most critical accounting policies have a significant impact on the preparation of these consolidated financial statements. These policies include estimates and significant judgments that affect the reported amounts of assets, liabilities, revenue, and expenses, and related disclosures of contingent assets and liabilities. We continue to have the same critical accounting policies as are described in Item 7, beginning on page 39, in our Annual Report on Form 10-K for fiscal year 2011 filed with the SEC on October 4, 2011. Those policies and the estimates involved in their application relate to revenue recognition; inventory reserves; share-based compensation; warranty reserves; purchase price allocation for business combinations; impairment of goodwill and indefinite lived intangible assets; income tax contingencies; and deferred tax valuation allowances. We continue to evaluate our estimates and judgments on an on-going basis. By their nature, these policies require management to make difficult and subjective judgments, often on matters that are inherently uncertain. Our estimates and judgments are based on our historical experience, terms of existing contracts, our observance of trends in the industry, information provided by our customers, and information available from other outside sources, as appropriate.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

All dollar amounts in this Item 3 are in thousands.

Certain of our foreign operations enter into transactions in currencies other than their functional currency, primarily the U.S. dollar and the Euro. We also have foreign currency exposure arising from the translation of our net equity investment in our foreign operations to U.S. dollars. We generally view our investments in foreign operations with functional currencies other than the U.S. dollar as long-term. The currencies to which we are exposed are the British pound, Canadian dollar, Chinese yuan, Danish kroner, and Euro. A 10% devaluation in the functional currencies, relative to the U.S. dollar, at January 31, 2012 and July 31, 2011 would result in a reduction of stockholders’ equity of approximately $950 and $1,458, respectively.

Our cash and investments include cash equivalents, which we consider to be investments purchased with original maturities of three months or less. At January 31, 2012, we did not have any held-to-maturity marketable securities having maturities from the time of purchase in excess of three months, which would be stated at amortized cost. Total net interest income for the three and six months ended January 31, 2012 was $133 and $269, respectively. An interest rate change of 10% would not have a material impact on the fair value of our investment portfolio or on future earnings.

 

32


Table of Contents
Item 4. Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of January 31, 2012. The term “disclosure controls and procedures”, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions to be made regarding required disclosure. It should be noted that any system of controls and procedures, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met and that management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of January 31, 2012, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

There were no changes to our internal control over financial reporting during the quarter ended January 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II. OTHER INFORMATION

 

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for fiscal year 2011, which could materially affect our business, financial condition, and future operating results. The risks described in our Annual Report on Form 10-K are not the only risks that we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and operating results. There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for fiscal year 2011.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table contains information about purchases by us of our equity securities during the three months ended January 31, 2012.

 

Period

 

Total Number of Shares
Purchased (1) (2) (3)

 

Average Price Paid
per Share (4)

 

Total Number of Shares
Purchased as Part of Publicly
Announced Plans or
Programs

 

Maximum Number (or
Approximate Dollar Value) of
Shares that May Yet Be
Purchased Under the Plans or
Programs

11/1/11-11/30/11   55,120   $54.94   54,690   $                 -
12/1/11-12/31/11   15,076   54.29   14,732   29,200,828
1/1/12-1/31/12   318   58.50   -   29,200,828
 

 

   

 

 

Total

  70,514   $54.81   69,422  
 

 

   

 

 

 

(1) Includes 430, 344 and 318 shares of our common stock surrendered by employees in order to meet tax withholding obligations in connection with the vesting of restricted stock awards in November 2011, December 2011 and January 2012, respectively.
(2) Includes 54,690, shares of our common stock purchased in open-market transactions in November 2011. These shares were purchased pursuant to a repurchase program authorized by the Board that was announced on December 9, 2010 to repurchase up to $30.0 million of our common stock. During the second quarter of fiscal year 2012, we repurchased 54,690 shares of our common stock under this repurchase program for $3.0 million at an average purchase price of $54.95 per share. The repurchase program has no remaining funds for additional purchases.
(3) Includes 14,732, shares of our common stock purchased in open-market transactions in December 2011. These shares were purchased pursuant to a repurchase program authorized by the Board that was announced on December 8, 2011 to repurchase up to $30.0 million of our common stock. During the second quarter of fiscal year 2012, we repurchased 14,732 shares of our common stock under this repurchase program for $0.8 million at an average purchase price of $54.25 per share. The repurchase program does not have a fixed expiration date.

 

33


Table of Contents
(4) For purposes of determining the number of shares to be surrendered by employees to meet tax withholding obligations, the price per share deemed to be paid was the closing price of our common stock on the NASDAQ Global Select Market on the vesting date.

 

Item 4. Mine Safety Disclosures

Not applicable.

 

34


Table of Contents
Item 6. Exhibits

 

Exhibit

 

Description

31.1   Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
31.2   Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
32.1   Certification of Principal Executive Officer pursuant to Rule 13a-14(b)/Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended
32.2   Certification of Principal Financial Officer pursuant to Rule 13a-14(b)/Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended
101.INS **   XBRL Instance Document.
101.SCH **   XBRL Taxonomy Extension Schema Document.
101.CAL **   XBRL Taxonomy Calculation Linkbase Document.
101.LAB **   XBRL Taxonomy Label Linkbase Document.
101.PRE **   XBRL Taxonomy Presentation Linkbase Document.
101.DEF **   XBRL Taxonomy Extension Definition Linkbase Document.

 

** Submitted electronically herewith.

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at January 31, 2012 and July 31, 2011, (ii) Condensed Consolidated Statements of Operations for the three and six months ended January 31, 2012 and January 31, 2011, (iii) Condensed Consolidated Statements of Cash Flows for the six months ended January 31, 2012 and January 31, 2011 and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.

In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, is deemed not filed for purposes of section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.

 

35


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      ANALOGIC CORPORATION
Date: March 7, 2012       /s/ James W. Green
      James W. Green
      President and Chief Executive Officer
      (Principal Executive Officer)
     
Date: March 7, 2012       /s/ Michael L. Levitz
     

Michael L. Levitz

Senior Vice President, Chief Financial Officer and Treasurer

(Principal Financial Officer)

 

36


Table of Contents

EXHIBIT INDEX

 

Exhibit

 

Description

31.1   Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
31.2   Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
32.1   Certification of Principal Executive Officer pursuant to Rule 13a-14(b)/Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended
32.2   Certification of Principal Financial Officer pursuant to Rule 13a-14(b)/Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended
101.INS **   XBRL Instance Document.
101.SCH **   XBRL Taxonomy Extension Schema Document.
101.CAL **   XBRL Taxonomy Calculation Linkbase Document.
101.LAB **   XBRL Taxonomy Label Linkbase Document.
101.PRE **   XBRL Taxonomy Presentation Linkbase Document.
101.DEF **   XBRL Taxonomy Extension Definition Linkbase Document.

 

** Submitted electronically herewith.

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at January 31, 2012 and July 31, 2011, (ii) Condensed Consolidated Statements of Operations for the three and six months ended January 31, 2012 and January 31, 2011, (iii) Condensed Consolidated Statements of Cash Flows for the six months ended January 31, 2012 and January 31, 2011 and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.

In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, is deemed not filed for purposes of section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.

 

37

XNAS:ALOG Analogic Corp Quarterly Report 10-Q Filling

Analogic Corp XNAS:ALOG Stock - Get Quarterly Report SEC Filing of Analogic Corp XNAS:ALOG stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

XNAS:ALOG Analogic Corp Quarterly Report 10-Q Filing - 1/31/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:ALOG Analogic Corp Insider Activity 4/A Filing - 10/3/2012  |  Next: XNAS:ALOG Analogic Corp Quarterly Report 10-Q Filing - 4/30/2012